January 28, 2022 -- Charles River Laboratories has expanded its strategic partnership with SAMDI Tech. The expanded agreement will provide Charles River's clients seamless access to the label-free, high-throughput screening mass spectrometry (MS) platform in drug discovery.
Under the existing partnership, established in 2018, SAMDI Tech clients have access to Charles River's collection of lead-like compounds for high-throughput screening.
SAMDI's technology combines self-assembled monolayers and matrix-assisted laser desorption/ionization (MALDI) MS and addresses the throughput and sample preparation limitations of traditional MS screening methods. The combination of Charles River's end-to-end portfolio and scientific bench with SAMDI Tech's innovative technology and expertise in assay solutions has the potential to significantly accelerate and augment clients' discovery efforts by measuring biochemical activities and binding events for virtually any target, according to the firms.
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies, and leading academic institutions around the globe accelerate their research and drug development efforts.